Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNK-UT002
- Development stage
- Unknown
- Lead developer
- ST Phi Therapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
CNK-UT002 is an allogeneic T-cell therapy developed by ST Phi Therapeutics, utilizing the company's proprietary CNK-UT platform. The therapy involves T cells engineered with a chimeric NK receptor (CNK) designed to recognize a broad spectrum of NK cell receptor ligands, such as NKG2D ligands, which are frequently overexpressed on the surface of various tumor cells. This approach allows the engineered T cells to recognize and eliminate tumor cells across multiple indications, including solid tumors and T-cell malignancies. CNK-UT002 is currently being evaluated in Phase 1 clinical trials for solid tumors and is in IND-enabling development for T-cell leukemia and lymphoma.
- Other names
- CNK-UT
02
Targets
MICB (Major histocompatibility complex class i-related protein B)NCR2 (Natural cytotoxicity triggering receptor 2)
Beyond the preview
Go deeper on CNK-UT002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNK-UT002.